Efficacy of erythromycin combined with methylprednisolone sodium succinate of reduced dosage in treatment of severe mycoplasma pneumonia in children
Objective To investigate the efficacy of erythromycin in combination with a minimal dose of methylpredniso-lone sodium succinate in treating severe mycoplasma pneumonia in children.Methods A total of 100 children with severe my-coplasma pneumonia admitted to the First Affiliated Hospital of Anhui University of Science and Technology from January 2023 to May 2024 were enrolled in this study and divided into the observation group and control group by random number method,with 50 in each group.The patients in the control group were treated with erythromycin alone while those in the observation group with erythromycin combined with methylprednisolone sodium succinate of reduced dosage.The clinical efficacy,time to defervescence,time to relief of cough and sputum,time to disappearance of lung rales,hospitalization duration,changes in levels of inflammatory factors such as C-reactive protein(CRP),interleukin-6(IL-6),and tumor necrosis factor-α(TNF-α)before and after treatment,as well as changes in levels of pulmonary function indicators including peak expiratory flow(PEF),forced vital capacity(FVC),and forced expiratory volume in one second(FEV1),changes in Clinical Pulmonary Infection Score(CIPS)and incidence of adverse reactions were compared between the two groups.Results The overall effective rate in the observation group reached 98.00%,surpassing that of 84.00%in the control(χ2=4.396,P＜0.05).The time to defervescence,relief of cough and sputum,disappearance of lung rales,and hospitalization duration in the observation group were(3.59±0.58)d,(5.18±0.95)d,(5.68±0.79)d,and(15.19±2.00)d,respectively,all of which were significantly shorter than those in the control((4.56±0.65)d,(7.72±1.00)d,(7.35±0.85)d,(17.45±2.12)d)(t=7.873,13.021,10.176,5.483,all P＜0.001).The levels of CRP,IL-6,and TNF-α in the observation group after treatment were(12.59±2.00)mg·L-1,(7.23±1.05)ng·L-1,and(1.32±0.20)mg·L-1,respectively,all of which were lower than those in the control((16.92±2.12)mg·L-1,(10.45±1.63)ng·L-1,(1.70±0.14)mg·L-1),showing statistically significant differences(t=10.505,11.743,11.006,all P＜0.001).The levels of PEF,FVC,and FEV1 in the observation group after treatment were(198.54±7.95)L·min-1,(1.79±0.30)L,and(1.77±0.13)L,respectively,all of which were higher than those in the control((166.92±8.54)L·min-1,(1.50±0.27)L,(1.45±0.15)L),and the differences were statistically significant(t=19.163,5.081,8.835,all P＜0.001).The CIPS score in the observation group was(3.23±0.59)points,which was remarkably lower than that of(4.23±0.66)points in the control(t=7.988,P＜0.001).The incidence of adverse reactions was 4.00%in both groups,demonstrating no statistically significant difference(χ2=0.000,P＞0.05).Conclusion In the treatment of severe mycoplasma pneumonia in children,erythromycin combined with methylprednisolone sodium suc-cinate demonstrates significant efficacy by improving inflammation,enhancing pulmonary function and alleviating clinical symptoms.Mean-while,it has a low incidence of adverse reactions and high safety profile.
Children with severe illnessMycoplasma pneumoniaErythromycinMethylprednisolone sodium succinateClini-cal efficacyInflammatory responseLung functionClinical Pulmonary Infection scoreAdverse reaction
万方数据
维普
